NPI 1043515034: Open Payments
NPI 1043515034. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,166 in 102 payments from 17 companies in 2025. Trend: 2023 $1,439 · 2024 $1,876 · 2025 $2,166
Food & beverage: $1,875Education: $291
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 18 | $444 |
| ABBVIE INC. | 16 | $358 |
| Organogenesis Inc. | 8 | $181 |
| GENZYME CORPORATION | 6 | $181 |
| LEO Pharma Inc. | 9 | $160 |
| UCB, Inc. | 10 | $149 |
| Lilly USA, LLC | 10 | $146 |
| Regeneron Healthcare Solutions, Inc. | 2 | $121 |
| Novartis Pharmaceuticals Corporation | 6 | $114 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $74 |
Products named: TREMFYA, DUPIXENT, RINVOQ, Bimzelx, ADBRY, SKYRIZI, TALTZ, COSENTYX.
